Sign in
Taking peopleNo phase

GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE

Key facts

Who runs it
Imperial College London
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
36 people, planned
Started
16 Apr 2025
Planned end
31 Jul 2026
Type of study
Interventional, 2 groups
Treatments tested
  • FLUENZ
  • Influenza challenge virus
Record updated
20 April 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Adults aged between 18-55 years inclusive
  • Sero-suitable as defined by a serum micro-neutralisation titre <1:20
  • Female participant who is not of child-bearing potential as assessed by an investigator OR is willing and able to use contraception as described in the protocol
  • Male participants who are willing to use one of the contraception methods described in the protocol
  • In good health with no clinically significant medical conditions

Who cannot take part

  • Inhaled bronchodilator/inhaled steroid use within the last 12 months before Day 0
  • Receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months before Day 0
  • Receipt of any vaccine within 30 days of Day -14
  • Receipt of blood/blood products/loss (including blood donations) of 550 mL or more of blood during the 3 months prior to Day -14
  • Significant history/presence of drug/alcohol misuse by self-report
  • Current use of drugs through nose inhalation or inhaled route including recreational drugs
  • Anyone with any of the following contraindications to receiving the Fluenz Tetra Vaccine:; Allergy to gentamicin, gelatin or the other ingredients of the fluenz vaccine
  • History of clinically significant/currently active conditions;; Cardiovascular, thromboembolic/cerebrovascular disease; Types of chronic respiratory disease in adulthood; Significant wheeze in the past; Respiratory symptoms including wheeze, resulting in hospitalisation; Known bronchial hyperactivity to viruses; Diabetes mellitus; Migraine with associated symptoms like hemiplegia/vision loss. Cluster headache/migraine/prophylactic treatment for migraine; History of autoimmune disease/known immunodeficiency of any cause; Immunosuppression; Known coagulation disorder/anticoagulant therapy; Psychiatric illness including participants with a history of depression and/or anxiety with associated psychiatric comorbidities; Other major disease that, under the PI's discretion, could interfere with the participant completing the study
  • Concurrent serious illness including history of malignancy that could interfere with the study or a participant completing the study
  • Known IgA deficiency/immotile cilia syndrome/Kartagener's syndrome
  • Significant abnormality altering the anatomy/function of the nose or nasopharynx, a clinically significant history of epistaxis within the last 3 months, nasal/sinus surgery within 6 months of Day 0, including nasopharyngeal malignancy, arterio-venous malformation, or undiagnosed nasopharyngeal mass
  • Acute upper respiratory tract infection in the past 6 weeks
  • Any significant medical condition/prescribed drug, under the PI's discretion
  • History of anaphylaxis and/or a history of severe allergic reaction or significant intolerance to any food/drug, as assessed by the PI
  • Clinically active rhinitis (including hay fever)/history of moderate to severe rhinitis/history of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and/or requiring regular nasal corticosteroids on an at least weekly basis, within 30 days of enrolment
  • Presence of cold-like symptoms and/or fever on Day -14 or Day 0
  • Regular smoking and/or vaping and/or using nicotine-containing products in the past 3 months OR >5 pack-year lifetime history by self-report (5 pack years is equivalent to one pack of 20 cigarettes per day for 5 years)

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

This trial is currently available in United Kingdom.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This experimental medicine study aims to compare immune responses in healthy adult volunteers aged 18-55 years against influenza vaccination and infection in the upper and lower respiratory tract, following administration of a live-attenuated influenza vaccine delivered by nasal spray versus influenza A (H3N2) viral challenge.

The 2 groups in the trial

  • LAIVTreatment being tested

    Treatment: FLUENZ

  • IAV ChallengeTreatment being tested

    Treatment: Influenza challenge virus

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Two-arm, Non-randomised, Open-label Experimental Medicine Study to Compare Immune Responses Between Healthy Volunteers Aged 18-55years Receiving Either an Intranasal Live-attenuated Influenza Vaccine or Viral Challenge With GMP Influenza A/Belgium/4217/2015 (H3N2)
Criteria questions
Built from NCT06620185, who can take part
Record updated
20 April 2026